Tysabri Liability: Biogen's Dialogue With FDA Helps Get Suit Tossed
Judge finds Tysabri label warnings about brain infection were adequate and that there is 'clear evidence' FDA would not have approved a labeling change.
You may also be interested in...
Survey finds patient assign greatest value to a drug’s effect on multiple sclerosis symptoms.
Multiple sclerosis and Crohn’s disease patients with anti-JC virus antibodies who have previously taken other immunosuppressants have a 1.1% risk of developing the deadly neurological condition after taking Biogen Idec /Elan’s Tysabri for more than two years.
Biogen Idec expects to re-launch the multiple sclerosis therapy in July.